Sign in
Not yet taking people in United StatesPhase 2

Ketone monitoring to lower ketoacidosis risk in type 1 diabetes taking an SGLT2 inhibitor

Tests ketone monitoring education in adults with type 1 diabetes taking sotagliflozin.

Key facts

Who runs it
AdventHealth Translational Research Institute
Where
Orlando, United StatesSee the site
Trial code
Registry title
Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors
Status
Not yet recruiting
Phase
Phase 2
People taking part
75 people, planned
Started
Jun 2026
Expected to end
Apr 2030
Type of study
Interventional
Treatments tested
  • SGLT-2 inhibitor (Sotagliflozin)
  • Insulin withdrawal test (IWT)
Record updated
19 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 40 with type 1 diabetes. It tests a ketone monitoring education plan for people taking an SGLT2 inhibitor.

Age
18 to 40 years
Sex
Men and women who are not pregnant
Disease stage
Type 1 diabetes with HbA1c below 9 % (75 mmol/mol), treated with multiple daily insulin injections, an insulin pump, or an advanced insulin delivery system
Earlier treatment
Cannot have used an SGLT2 inhibitor within 4 weeks before screening

Main reasons for not taking part

  • Pregnancy, breastfeeding, or planning to become pregnant
  • Any form of diabetes other than type 1
  • Diabetic ketoacidosis within 6 months before screening
  • eGFR below 30 mL/min/1.73m²
  • Organ transplant, or active liver disease or cirrhosis

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Men and nonpregnant women ≥18 years and older
  • Diagnosis of T1D according to American Diabetes Association (ADA) criteria
  • HbA1c < 9 %
  • Participants treated with multiple daily injections of insulin, insulin pump, or advanced insulin delivery systems
  • Has provided written informed consent to participate in the study
  • Must be willing to wear the investigational device
  • Use of adequate contraception for the duration of the study by women of childbearing potential

Who cannot take part

  • Chronic systematic corticosteroids (>4 consecutive weeks) within 6 months before screening
  • Recent myocardial infarction, stroke, hospitalization for unstable angina or heart failure within 3 months prior to screening
  • Inability to perform the study follow up/ unwilling to wear the investigational device
  • Any form of diabetes other than T1D
  • History of diabetic ketoacidosis within 6 months of screening
  • History of multiple (≥ 3 infections) genital mycotic infections within 6 months of screening
  • Hypotension at screening is defined as systolic blood pressure < 90 and diastolic blood pressure < 60 with symptoms of low blood pressure (confusion, dizziness, lightheadedness, fainting, heart palpitations)
  • History of a level 3 hypoglycemic event (as defined by ADA criteria) within 3 months of screening
  • New York Heart Association Class IV heart failure
  • Impairment of systems and organs that may increase their risk of participating in the intervention study or compromise the results (for example: end stage kidney disease, active liver dysfunction, gastroparesis, anemia, ), organ transplant
  • Cancer treatment (excluding non-melanoma skin cancer treated by excision, carcinoma in situ of the cervix or uterus, ductal breast cancer in situ, resected non-metastatic breast or prostate cancer) within one year of screening
  • Active Hepatitis B or C, acquired immunodeficiency syndrome (HIV infection controlled with suppressive medications is allowed) or tuberculosis
  • Current or past history of decompensated cirrhosis (defined as variceal bleeding, ascites, or hepatic encephalopathy), and/or known diagnosis of cirrhosis
  • Heavy alcohol use (for men, ≥5 drinks on any day or ≥15 drinks per week; for women, ≥4 drinks on any day or ≥8 drinks per week) at screening, history of alcohol use disorder or binge drinking
  • Any condition or factor that would compromise the participant's safety or the scientific integrity of the study (cognitive impairment, bipolar disorder, or history of eating disorder)
  • Use of sodium-glucose cotransporter 2 inhibitors within 4 weeks prior to screening
  • CKD-EPI estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m²
  • Abnormal liver function at screening defined as any of the following: aspartate aminotransferase (AST) >2X upper limit of the normal reference range (ULN), ALT >2X ULN, serum total bilirubin (TB) >1.5X ULN
  • Pregnancy, lactation or planning to become pregnant
  • People with T1D using weekly insulin (when approved)
  • People who are unwilling to consume at least 20% of calories from carbohydrates

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

Where in United States

  • AdventHealth Translational Research InstituteOrlando, United StatesContact: JaWanda ThackerNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this research is to see how well a special education plan using continuous ketone monitoring (DGK) works to lower the risk of a condition called diabetic ketoacidosis (DKA) in people with type 1 diabetes (T1D) taking SGLT2 inhibitors (a type of medication commonly used to treat type 2 diabetes). This special education plan is compared to a general education plan and considers the higher risk of DKA when using medicines like SGLT2 inhibitors.

The group in the trial

  • People with Type 1 DiabetesOther group

    Treatment: SGLT-2 inhibitor (Sotagliflozin) and Insulin withdrawal test (IWT)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT2 Inhibitors
Plain-language title
Ketone monitoring to lower ketoacidosis risk in type 1 diabetes taking an SGLT2 inhibitorGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07421518, who can take part
Record updated
19 February 2026